A Phase I study evaluating the safety, tolerability, and pharmacokinetics of RIM730
Latest Information Update: 30 Mar 2023
At a glance
- Drugs RIM 730 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 28 Mar 2023 According to Sirnaomics media release, company anticipates filing an IND in the first quarter of 2023.
- 31 Mar 2022 New trial record
- 29 Mar 2022 According to RNAimmune media release, company anticipates filing an IND with the FDA in the fourth quarter of 2022 to initiate this study.